Introduction 02-adrenoceptor agonists have played a key role in the treatment of asthma for some 30 years, being used both for the relief and prophylaxis of symptoms. Although their use is widespread, controversy continues regarding the role played by these agents in terms of the observed increases in asthma mortality, and deterioration in disease control apparently associated with their regular use. The more recent introduction of long acting 032-adrenoceptor agonists has further fuelled the debate, particularly with regard to the issue of P2-adrenoceptor tolerance which may theoretically occur with continuous use.
In this review the primary aim is to reappraise current thinking regarding the question of tolerance, and to assess its possible clinical relevance. The issue of safety and increased mortality in relation to the use of 02-adrenoceptor agonists has been extensively reviewed elsewhere and will only be referred to here in the context of tolerance [1] [2] [3] [4] [5] [6] [7] . The facilitatory effects of disease modifying agents such as corticosteroids on 02-receptors and tachyphylaxis will also be discussed, as this has implications in clinical situations where the two therapies are often used concurrently. Finally, we will consider whether the present state of knowledge requires an evolution in the current asthma management guidelines in terms of the rational use of P32-adrenoceptor agonists. Homologous desensitisation is the more rapid process and involves a rapid uncoupling of the receptor from adenylate cyclase, internalisation of the receptor from the cell surface, cyclic AMP independent phosphorylation of the receptor, and a slower down-regulation of the receptor, characterised by a loss of total receptor binding sites from the cell. Heterologous desensitisation may involve receptor phosphorylation by a cyclic-AMP dependent protein kinase (a negative feedback mechanism) [8] .
Tolerance to systemic f2-mediated effects, and to airway P2-effects in normal subjects is well recognised [9, 10] . Repsher et al. [11] found that tolerance to the duration, but not the peak bronchodilator response to a single dose of salbutamol (170 g,g) developed after 91 days treatment with salbutamol, 170 gg four times daily when compared with the response prior to treatment, but without placebo control. Weber and coworkers were able to demonstrate tolerance to both the peak and duration of the bronchodilator response to cumulative doses of terbutaline in a group of 13 asthmatics, following 12 weeks treatment with inhaled terbutaline, 500 kg four times daily. Eight of this group were receiving corticosteroid therapy, and in this small sample this did appear to protect against the development of tolerance [12] . In contrast, several other studies assessing treatment with both oral and inhaled 02-adrenoceptor agonists by means of bronchodilator responses to single and cumulative doses of inhaled, intravenous, and subcutaneous I2-adrenoceptor agonists have failed to show evidence of tolerance [13] [14] [15] .
Whilst these studies examined the effects of conventional doses of ,B2-adrenoceptor agonists it could be predicted that higher doses producing greater receptor occupancy may be likely to produce tolerance, on the other hand studies have demonstrated that, at least when given acutely higher than normal doses of P2-adrenoceptor agonists produced additional benefit in terms of bronchodilatation, without significant additional side effects [16] . High dose therapy using both inhalers and nebulisers has been examined in this regard. Following a 2 week washout of 02-adrenoceptor agonists, Lipworth et al. [17] compared systemic and bronchodilator responses to cumulative doses of inhaled terbutaline following 4 weeks treatment with conventional doses of terbutaline (500 kg, four times daily via a spacer) or high dose treatment (2000 kg, four times daily via a spacer) in 11 patients with chronic obstructive airways disease. Whilst systemic responses were blunted to a significantly greater degree following high dose treatment compared with low dose, there were no differences in the bronchodilator responses. Teale and co-workers [18] studied the bronchodilator responses of a group of 10 patients with severe obstructive airways disease both before and during 3 months treatment with nebulised terbutaline, 5 mg four times daily. Baseline PEFR and FVC improved during the treatment period, and there was no reduction in peak bronchodilator response to cumulative doses of terbutaline. This study did not however include a washout period, and was not placebo controlled.
Antibronchoconstrictor tolerance
With regard to the antibronchoconstrictor effects of these drugs, concerns have been raised in two main Review 111 areas. Firstly, does tolerance develop to these properties with chronic use? Secondly, does rebound hyperreactivity occur after cessation of regular therapy? When considering these issues it is important to distinguish between the various stimuli used to provoke bronchoconstriction. Whilst methacholine and histamine are predominantly direct smooth muscle stimulants, allergen challenge and AMP act indirectly by stimulating mast cells, with mediator release subsequently producing bronchospasm. The mechanism by which exercise induces bronchoconstriction in susceptible individuals remains unclear but it may involve changes in the osmolality of the pulmonary extracellular fluid [19] . There may therefore be differential effects of ,32-adrenoceptor agonists on these varied stimuli, with a consequent difference in susceptibility to tolerance.
Cockcroft et al. [20] studied the response of 11 mild asthmatics to allergen and methacholine challenge. Responses were measured before, and after 2 weeks treatment with inhaled salbutamol, in a dose of 200 gg four times daily or placebo, with and without administration of salbutamol immediately prior to the provocation test. Having withheld salbutamol they showed no change in the response to methacholine challenge whilst there was an increase in sensitivity to allergen, equivalent to 0.91 doubling doses, following regular treatment with salbutamol compared with placebo. Furthermore, there was a reduction in the acute protective effect of salbutamol against both allergen and methacholine challenge following regular treatment with salbutamol, although the effect was more marked with allergen challenge. It was speculated that this may have been a result of P2-receptor down-regulation allowing enhanced mast cell mediator release by reducing the ability of the agonists to stabilise the mast cell, a p2-receptor mediated process. In this regard it has also been shown, in 12 mild asthmatics, following 7 days treatment with terbutaline, that tolerance developed to the protective effect of terbutaline against AMP induced bronchospasm. The reduction in protection was of the order of 2.1 doubling doses [21] . As in the study by Cockcroft a reduction was seen in the protection against methacholine challenge. However, both the initial level of protection and the subsequent reduction were less than was the case for AMP. Results using histamine as the stimulus have been less consistent, with some groups demonstrating a statistically significant increase in reactivity following regular treatment with P2-adrenoceptor agonists whilst others have not [15, [22] [23] [24] [25] . In the case of exercise induced bronchospasm a reduction in the protective effect of salbutamol has been demonstrated in six mild asthmatics after between 4 and 20 weeks treatment with oral salbutamol. This effect was not however seen in six adolescents receiving inhaled salbutamol [26] .
All these results must be interpreted in the light of an awareness of the intrinsic variability of bronchial hyperreactivity. Even in an ostensibly stable clinical situation, measurements of reactivity can vary by up to two-fold, i.e. +/-one doubling dose [27] . It can therefore be seen that whilst statistically significant, some of the findings discussed may be of more doubtful clinical significance. It may be that although as a whole the changes seen are relatively small when compared with normal biological variability, in a subgroup of more severe asthmatics such changes may assume relatively more importance. It is, however, worth noting that studies quoted have used relatively mild asthmatics not receiving disease modifying therapy, and the results should not automatically be extrapolated to more severe cases.
Whilst investigating the question of tolerance to antibronchoconstrictor effects it was observed in some studies, that bronchial reactivity appeared to increase in the period immediately after stopping regular ,-adenoceptor agonist therapy [23] . Vathenen et al. [28] measured bronchial reactivity to histamine for up to 24 h after completing 2 weeks treatment with terbutaline. As in other studies, they demonstrated a significant reduction in the protection afforded by a dose of terbutaline against histamine induced bronchoconstriction following this treatment. They also demonstrated an increase in bronchial hyperreactivity after stopping treatment with a maximum increase of 1.5 doubling doses at 23 h. Larsson and co-workers [29] demonstrated a trend towards increased reactivity to allergen challenge 48 h after stopping treatment with oral terbutaline. Down-regulation of 02-receptors has been invoked as an explanation for this phenomenon, as this may render the subject less able to respond to endogenous catecholamines. The relevance of these relatively small changes to disease control remains unclear, and in any event the sudden cessation of regular therapy is a relatively unlikely clinical scenario.
In [31] where regular treatment with ipratropium bromide or salbutamol was associated with a greater decline in FEVy compared with on demand treatment (mean difference of 52 ml per year) is difficult to interpret, primarily because bronchial hyperreactivity, symptom control, and quality of life were unaltered whilst data on bronchodilator dose-response curves were not reported. Finally, more recently, Chapman et al. [32] reported that regular salbutamol improved symptoms compared with as required treatment although parameters of disease activity were not evaluated as such.
It therefore appears that if regular 02-adrenoceptor agonist therapy has a deleterious effect on lung function or disease control, the effect is of small magnitude, and perhaps not of clinical relevance. The question as to whether tolerance is responsible for altered disease control remains unanswered on the basis of the available studies.
Long-acting 032-adrenoceptor agonists Salmeterol and formoterol are both 02-adrenoceptor agonists with a duration of bronchodilator action of at least 12 h [33, 34] . Salmeterol is a partial agonist at the airway 52-receptor in vitro, whilst formoterol is a full agonist in this situation [35] . Whilst such a prolonged duration of bronchodilatation may be con-sidered beneficial, particularly with regard to nocturnal symptoms of asthma, it may be anticipated that the prolonged receptor occupancy produced by this newer group of P2-adrenoceptor agonists would be more likely to result in receptor down-regulation, and therefore result in tolerance, than is the case with the shorter acting drugs. Furthermore, the distinction between the full agonist activity of formoterol, and the partial agonism of salmeterol may be relevant in this regard. In the light of these theoretical concerns several studies have been carried out to evaluate the possible occurrence of tolerance to both the bronchodilator and antibronchoconstrictor effects of these agents.
Bronchodilator tolerance
Ullman et al. [36] treated 12 asthmatics (11 of whom were taking inhaled corticosteroids) with salmeterol 50 jig twice daily or salbutamol 200 gg four times daily for 2 weeks, but without a placebo control period. At the end of each treatment period doseresponse curves to salbutamol were constructed, using a total cumulative dose of 900 jug. During the treatment period asthma control was said to be significantly better with salmeterol compared with salbutamol, in terms of peak flow measurements, sleep quality and degree of dyspnoea. This study also concluded there was no evidence of tolerance to the bronchodilator dose-response to salbutamol, although the methodology employed may have masked this, particularly as they were unable to reproduce the well documented phenomenon of systemic tolerance following chronic dosing with salbutamol. The results may therefore reflect the absence of a run-in period without P2-adrenoceptor agonists prior to the study such that tolerance could have been present from the outset. Furthermore, the basal values of forced expiratory volume in 1 s (FEVy) and forced vital capacity (FVC) were significantly increased after treatment with salmeterol compared with pretreatment values. This makes comparison between dose-response curves difficult, since whilst the absolute final values of FEVI and FVC were similar, the change from baseline was less after treatment with salmeterol. It was not possible to elucidate whether this reflects the fact that the patients had reached a ceiling in the dose-response curve or whether this was indeed a manifestation of tolerance. Other studies have concurred in finding no evidence of tolerance to the bronchodilator effects of salmeterol although the findings were based on responses to single doses of salmeterol, and in the absence of a run-in period prior to the study [37, 38] .
Arvidsson and co-workers [39] evaluated formoterol in 20 asthmatics (15 of whom were using inhaled corticosteroids) with regard to symptom control and tolerance. Patients received formoterol, 12 jig twice daily, in a crossover study with [15] demonstrated lymphocyte P2-receptor down-regulation in asthmatics following treatment with oral terbutaline whilst bronchodilator responses to inhaled isoprenaline and subcutaneous terbutaline were maintained [15] . Hauck and co-workers examined the relationship between lymphocyte and pulmonary P2-receptors directly [43] . Eighteen patients undergoing lung resection were evaluated. Ten received subcutaneous terbutaline 0.5 mg twice daily for 24-72 h preoperatively whilst eight received no treatment. It was found that whilst mononuclear leucocyte 02-receptor density was reduced by treatment, there was no significant change in lung receptor density. Whilst this could represent a constitutive difference in susceptibility of the two receptor populations to down-regulation it is also possible that inadequate tissue penetration was achieved with the dose and route of administration used, or that the pulmonary receptors were already down-regulated as a result of previous exposure to fB2-adrenoceptor agonists, as was the case in half of the treatment group. Thus the validity of this technique as an index of pulmonary P2-receptor function remains unclear.
However, recently abstracted in vitro data has indeed suggested that lung 02-receptors become down-regulated on exposure to long-acting, but not short-acting 02-adrenoceptor agonists [44] . Interestingly it was also found that salmeterol increased the receptor association constant, a finding mirrored in our two studies with formoterol [40, 41] . This perhaps infers that increased receptor affinity may in some way be compensating for the reduction in receptor density. Quing et al. [45] have also recently reported, in abstract form, that in normal subjects both lung (as assessed by positron emission tomography) and mononuclear leucocyte P2-receptors undergo down-regulation following exposure to 2-adrenoceptor agonists, and concluded that lymphocyte P2-receptor density may be used as a surrogate for following airway 032-effects [45] .
Antibronchoconstrictor tolerance
Following acute dosing, salmeterol and formoterol produce prolonged protection against a variety of bronchoconstrictor stimuli [46] [47] [48] . Studies have been performed to elucidate whether tolerance develops to this antibronchoconstrictor property. Cheung and co-workers studied 24 patients with mild asthma requiring treatment with salbutamol on an as required basis only [37] . They received 8 weeks treatment with either salmeterol 50 ,ug twice daily or placebo. The protective effect of salmeterol against metha-choline induced bronchoconstriction was studied after the first dose, and again after 4 and 8 weeks of treatment. The challenges were performed 1 h after receiving a dose of salmeterol but this was preceded by a 36 h period during which medication was withheld. The results showed that the acute protective effect of salmeterol against histamine was markedly attenuated after 4 weeks of treatment. In this study salmeterol was given to a group of very mild asthmatics, not requiring disease modifying therapy, i.e. a group of patients who would not normally receive salmeterol as routine therapy. It may therefore not be valid to extrapolate these findings to more severe asthmatics. It is probably more meaningful to consider studies where the protective effect of salmeterol was evaluated within the normal dosing interval (i.e. at 12 h). Booth and co-workers studied a population of mild to moderate asthmatics, the majority of whom (73%) were receiving treatment with inhaled corticosteroids [49] . Subjects received 8 weeks treatment with placebo or salmeterol, 50 kg twice daily, and methacholine challenge tests were performed 12 h after the first dose, at 4 and 8 weeks of treatment, and during a subsequent washout period. In this group of patients the protective effect of salmeterol seen after the first dose (0.6-1.2 doubling doses) was not significantly altered after chronic dosing. Beach et al. [50] studied 20 patients, all of whom were receiving inhaled corticosteroids. Bronchial reactivity to methacholine was measured 24 and 72 h after ceasing 6 weeks of continuous treatment with salmeterol, 50 gg twice daily or salbutamol 400 kg twice daily, but without placebo control. There were no significant changes in bronchial hyperreactivity within or between the two treatment groups.
There is, however, evidence to show that tolerance develops to the protective effect of salmeterol against exercise induced bronchoconstriction, in a study where salmeterol 50 kg twice daily was compared with placebo given for 4 weeks, with exercise challenge performed 6 and 12 h after the first dose and at 4 weeks. Whilst salmeterol protected against exercise induced bronchoconstriction compared with placebo at 6 and 12 h after the first dose, there was no significant difference between salmeterol and placebo after 4 weeks of treatment [51] (Figure 2) . It is worth pointing out that the patients studied had only mild asthma, and only three patients were using inhaled corticosteroids. Recent data has compared the effect of salmeterol 50 kg twice daily for 4 weeks with placebo, in 17 asthmatics, all receiving inhaled corticosteroids, after an initial 2 week run-in without P2-adrenoceptor agonists. Whilst morning peak flows were improved during salmeterol treatment, histamine challenge performed 12 h after the last dose of each treatment period showed only minimal protection (i.e. 0.7 doubling doses) with salmeterol compared with placebo. Furthermore a bronchodilator dose-response curve to salbutamol performed 36 h after the last dose showed evidence of a parallel right shift after salmeterol compared with placebo with a four-fold greater dose of salbutamol being required to produce the same PEFR response [52] . Lymphocyte P2-receptor density showed a trend towards downregulation after treatment with salmeterol, with unchanged receptor affinity, compared with placebo or run-in. Thus it appears that salmeterol, like formoterol, produces bronchodilator tolerance which is mirrored by 02-receptor down-regulation.
Data
are not yet available regarding chronic dosing with formoterol in these situations. It may also be interesting to study the protective effect of chronic dosing with salmeterol or formoterol on bronchial reactivity to AMP, as experience with short-acting agonists suggests that this response may be more susceptible to tolerance, possibly because of the receptor mediated process involved in producing bronchospasm in this case.
The influence of disease modifying therapy
The use of disease modifying therapy is now advocated at an early stage in the management of asthma [53] . The influence of such therapy on the action of P2-adrenoceptor agonists is therefore of great clinical relevance.
Corticosteroids are thought to be heterologous regulators of ,-adrenoceptors in many tissues [54] . This includes considerable evidence to suggest that in vitro, corticosteroids modulate P2-receptor function on circulating lymphocytes. Hui et al. [55] demonstrated that a single dose of methylprednisolone restored P2-receptor density to normal values within 16 h, the receptors having previously been down-regulated by oral terbutaline therapy. The steroid had no effect on receptors that had not been down-regulated. A single dose of 100 mg oral prednisolone produced similar up-regulation, within 8 to 10 h of receiving Review 115 the drug [56] . The mechanism of this effect is not yet fully understood, but it may involve an increase in the rate of de novo synthesis of receptors or, a reversal or inhibition of internalisation of receptors from the cell surface. The human D2-adrenoceptor gene has at least three glucocorticoid response elements (GREs) in its promoter region. Activated glucocorticoid receptor-steroid complexes bind to these sites and increase gene transcription. Corticosteroids are also thought to promote the formation of the coupled, high affinity state of the receptor, which will in turn increase receptor function [54] . 02-adrenoceptor agonists are also thought to be able to influence the binding of corticosteroids to DNA. 0-adrenoceptor agonists can increase binding to cAMP response elements in human lung in vitro, and at the same time reduce binding to GREs [57] . In theory, this could suggest that in high concentrations 0-adrenoceptor agonists may inhibit the antiinflammatory actions of steroids.
Does up-regulation of p2-receptors in vitro correlate with improved function of airway 02-receptors?
Holgate et al. [10] studied normal subjects, in whom it is possible to reliably produce tolerance to the bronchodilator effects of 02-adrenoceptor agonists.
Having produced tolerance, they found that full bronchodilator sensitivity was restored 3-5 h after an intravenous injection of 200 mg hydrocortisone.
In the 1970s a small study of 10 asthmatics who were said to be 'refractory' to the bronchodilator effects of isoprenaline showed that a single dose of prednisolone restored bronchodilator responses within 1 h [58] . Brodde et al. [59] Time (months) 15 21 Placebo ( combined group, and was unchanged in the group receiving bronchodilator alone. Furthermore these effects were maintained over the 24 months of follow-up ( Figure 3) . In a smaller study of 27 asthmatic children, the combination of budesonide (400 jg daily) and terbutaline (2000 jg daily) produced a reduction in histamine reactivity with a 2.1 doubling dose difference compared with terbutaline plus placebo [25] . [40, 41] . With respect to the long-acting P2-adrenoceptor agonists such as salmeterol the question has arisen as to whether it is best to optimise the dose of inhaled corticosteroid in the step-up phase of management, or to add salmeterol to a lower dose of inhaled corticosteroid. In a recent study by Greening and co-workers, in a group of 429 mild asthmatics with persistent symptoms whilst taking beclomethasone dipropionate 400 ,ug daily, the addition of salmeterol 50 jig twice daily was more effective in controlling symptoms than increasing the dose of steroid to 1000 jig daily. Over the 6 month study period there was no difference between treatments in terms of the exacerbation rate [62] . It is perhaps not surprising that in the presence of prolonged bronchodilatation both symptoms and peak expiratory flow were significantly improved in the salmeterol limb of the trial. This study received methodological criticism in that beclomethasone dipropionate was delivered by metered dose inhaler whilst the salmeterol was delivered by dry powder device [63] . Thus it is likely that the study was heavily biased against the steroid limb in view of the notoriously poor inhaler technique with metered dose inhalers.
Other disease modifying therapies have been shown to have an effect on 52-receptor function. Ketotifen has been shown both to accelerate upregulation of previously down-regulated lymphocyte 2-receptors, and to attenuate down-regulation. This has been found to correlate with an attenuation of the tolerance to systemic, and airway f2-mediated effects in normal subjects [56, 64] . Ketotifen has also been shown to up-regulate lymphocyte P2-receptors in asthmatics, a change associated with an improvement in pre-bronchodilator peak flows but no change in reversibility [59] . The mechanism of this effect is not yet known but ketotifen may interfere with internalisation of 52-receptors. The anti-inflammatory agent nedocromil sodium has also been shown to prevent isoprenaline induced p2-receptor down-regulation of guinea-pig lung, in vitro [65] . In vivo studies using a suitable model of bronchodilator tolerance may therefore be informative in indicating novel applications for these compounds which, to date have had a limited role in the management of adult asthmatics. Review 117
